View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 25, 2022

Ranok gets FDA clearance for Phase I/II cancer trial

Subject enrolment in the CHAMP-1 trial is expected to begin in the first half of this year.

Ranok Therapeutics secured clearance from the US Food and Drug Administration (FDA) to stage a Phase I/II trial for its RNK05047 to treat advanced solid tumours and lymphomas.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Ranok anticipates commencing subject enrolment in the Phase I/II CHAMP-1 trial in the first half of this year.

Discovered and developed using the Chaperone-mediated Protein Degradation (CHAMP) platform of the company, RNK05047 is a small-molecule, BRD4-selective protein degrader.

Using Ranok’s capabilities in protein homeostasis and cellular chaperone network, the technology is claimed to degrade disease-linked proteins. 

Cellular chaperone network controls the proteins’ folding and stability.

Furthermore, CHAMP could boost the safety and efficacy of the drug by specifically acting on disease tissues, the company noted.

Ranok founder and CEO Weiwen Ying said: “We are looking forward to initiating this clinical study of the first small-molecule therapy based on our CHAMP platform technology.

“The bromodomain transcription factor BRD4 is a master regulator of oncogenes involved in diverse cancer types. RNK05047 is designed to selectively degrade BRD4 protein in a tumour-targeted fashion, which differentiates it from other investigational therapies.”

In November last year, the company signed an agreement with Pfizer to use and assess CHAMP platform technology on an undisclosed cancer target. 

The companies have not divulged the terms of the deal.

Ranok raised $40m in a Series B financing round led by Lapam Capital and Shanghai Healthcare Capital in August last year. It has raised funds worth more than $50m.

The funding will be used to support the continued development of advanced cancer programme and to extend its preclinical pipeline of new treatments that are based on the CHAMP platform.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena